Creative Medical Technology Holdings Inc. (CELZ) - Margin operasi

Creative Medical Technology is developing the AmnioStem platform, introducing innovations in regenerative therapy. An assessment of operating profitability demonstrates profit dynamics, where -256435.00 becomes the new value for this metric. A narrow business profile creates a dependency on future patents. Meanwhile, regulatory uncertainty and clinical trial costs create significant barriers to the company's potential growth.
Rincian metrik lan analitis perusahaan Creative Medical Technology Holdings, Inc. (CELZ)

Efficient air delivery of cellular materials minimizes logistics costs for Creative Medical Technology (CELZ), directly impacting the operating profit margin before interest and taxes. This ratio reflects the share of core business profit in revenue before financial expenses, allowing investors to assess real capital management efficiency and the company's operational resilience by analyzing the trends on this chart.